ArticleEuropean journal of gastroenterology & hepatology2026
Prognostic value of easy Albumin-Bilirubin score in liver cirrhosis: a comparison with established scoring systems.
Article in European journal of gastroenterology & hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsAccurate prognostication critical for managing liver cirrhosis. Existing tools [Child-Pugh, model for end-stage liver disease (MELD), MELD-sodium (MELD-Na), Albumin-Bilirubin (ALBI), and platelet ALBI (PALBI)] have limitations, including subjectivity, complexity, and reliance on logarithmic transformations. Simplified easy-ALBI (EZ-ALBI), a prognostic factor in hepatocellular carcinoma, is understudied in cirrhosis. The present study aimed to evaluate its prognostic value in cirrhosis, compare it with established scores, assess its consistent long-term performance, and define its clinical utility for risk stratification.
methodsThis retrospective study enrolled 501 cirrhotic patients (June 2018-June 2020), with a median follow-up of 42.3 months (interquartile range: 28.6-56.8 months); follow-up was terminated on 30 June 2025. EZ-ALBI was compared with Child-Pugh, MELD-Na, ALBI, and PALBI using correlation, survival (Kaplan-Meier), Cox regression, and receiver operating characteristic analyses.
resultsEZ-ALBI strongly correlated with ALBI ( r = 0.9460, P < 0.001). EZ-ALBI grade 3 was associated with shorter survival (29.9 vs. 65.5 months, P < 0.001) and served as an independent prognostic factor (hazard ratio = 3.944, 95% confidence interval: 1.772-8.777, P < 0.05). Its prognostic accuracy was consistent across 6-60 months (areas under the curves: 0.738-0.832), long-term performance (36-60 months) was comparable to MELD, MELD-Na, and ALBI, and outperformed Child-Pugh and PALBI in specific periods.
conclusionThe EZ-ALBI score is a simple, objective, and reliable prognostic tool for patients with liver cirrhosis, with consistent predictive value across follow-up periods, supporting its clinical utility for risk stratification. Notably, EZ-ALBI's simplicity (no logarithmic transformations) significantly enhances its practicality for bedside risk stratification, a key advantage in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.